Added to YB: 2025-11-12
Pitch date: 2025-11-06
QURE [neutral]
uniQure N.V.
-25.31%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.9B
Pitch Price
$26.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.44
P/E
-6.88
EV/Sales
107.85
Sector
Biotechnology
Category
growth
UniQure: (Hopefully) Progress on miRNA Therapeutics $qure
QURE (update): miQURE platform using atypical miR-451 scaffold avoids cellular machinery overload vs traditional miRNA. AMT-130 for Huntington's leads competitors in trials but complex delivery limits scalability. FDA shifted accelerated approval goalposts, delaying BLA to Q1'26 launch timeline despite unmet medical need.
Read full article (7 min)